Anova M, Lafage M, Birnbaum D: Localization of the 5’end with the MCF2 oncogene to human chromosome 15q15 q23. Cytogenet Genome Res 1992, 60(two):114?16. 57. Comoglio PM, Giordano S, Trusolino L: Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 2008, 7(6):504?16. 58. Nakajima M, Sawada H, Yamada Y, Watanabe A, Tatsumi M, Yamashita J, Matsuda M, Sakaguchi T, Hirao T, Nakano H, et al: The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 1999, 85(9):1894?902. 59. Dussault I, Bellon SF: From notion to reality: the extended road to c-Met and RON receptor tyrosine kinase inhibitors for the therapy of cancer. AntiCancer Agents Med Chem 2009, 9(2):221?29. 60. Eathiraj S, Palma R, Volckova E, Hirschi M, France DS, Ashwell MA, Chan TC: Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition element (c-Met) protein autophosphorylation by ARQ 197.(S,R,S)-AHPC-Me (hydrochloride) structure J Biol Chem 2011, 286(23):20666?0676. 61. Underiner TL, Herbertz T, Miknyoczki SJ: Discovery of small molecule c-Met inhibitors: evolution and profiles of clinical candidates. Anti-Cancer Agents Med Chem 2010, ten(1):7. 62. Choueiri TK, Vaishampayan U, Rosenberg JE, Logan TF, Harzstark AL, Bukowski RM, Rini BI, Srinivas S, Stein MN, Adams LM, et al: Phase II and biomarker study with the dual MET/VEGFR2inhibitor foretinib in individuals with papillary renal cell carcinoma. J Clin Oncol 2013, 31(2):181?86. 63. Muro K, Ryu MH, Yasui H, Nishina T, Ryoo BY, Boku N, Kang YK: A phase II study of tivantinib monotherapy in sufferers with previously treated sophisticated or recurrent gastric cancer [abstract]. J Clin Oncol 2012 (suppl):4082. http://asco.org/. 64. Bjornsti MA, Houghton PJ: The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004, 4(five):335?48. 65. Mart ME, MI P’ r, Redondo C, Alvarez MI, Salinas M, Fando JL: 4E binding protein 1 expression is inversely correlated to the progression of gastrointestinal cancers. Int J Biochem Cell Biol 2000, 32(6):633?42. 66. Cejka D, Preusser M, Woehrer A, Sieghart W, Strommer S, Werzowa J, Fuereder T, Wacheck V: Everolimus (RAD001) and anti-angiogenic cyclophosphamide show long-term control of gastric cancer growth in vivo.4′-Bromo-2,2′:6′,2”-terpyridine In stock Cancer Biol Ther 2008, 7(9):1377?385.PMID:33649994 67. Okamoto I, Doi T, Ohtsu A, Miyazaki M, Tsuya A, Kurei K, Kobayashi K, Nakagawa K: Phase I clinical and pharmacokinetic study of RAD001 (Everolimus) administered everyday to Japanese patients with sophisticated solid tumors. Jpn J Clin Oncol 2010, 40(1):17?three.68. Doi T, Muro K, Boku N, Yamada Y, Nishina T, Takiuchi H, Komatsu Y, Hamamoto Y, Ohno N, Fujita Y, et al: Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer. J Clin Oncol 2010, 28(11):1904?910. 69. Van Cutsem E, Yeh KH, Bang YJ, et al: Phase III trial of everolimus (EVE) in previously treated patients with advanced gastric cancer (AGC): GRANITE-1[abstract]. J Clin Oncol 2012(Suppl four):LBA3. http://asco.org/.doi:ten.1186/2050-7771-1-32 Cite this short article as: Qiu and Xu: The progress of targeted therapy in sophisticated gastric cancer. Biomarker Analysis 2013 1:32.Submit your next manuscript to BioMed Central and take full advantage of:?Convenient online submission ?Thorough peer overview ?No space constraints or colour figure charges ?Instant publication on acceptance ?Inclusion in PubMed, CAS, Scopus and Google Scholar.
